Promethera Biosciences Competitors and Similar CompaniesClear all

Promethera Biosciences's competitors and similar companies include Poxel, Gilead Sciences and Novartis.

	Promethera Biosciences Promethera Biosciences is a healthcare company developing cell therapy technologies for chronic liver diseases.	Poxel Poxelis a research integrated pharmaceutical company that develops products for metabolic diseases.	Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.
Founding Date	Founding Date 2009	Founding Date 2009	Founding Date 1987	Founding Date 1996
Type	Type Subsidiary	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare Technology	Tags Manufacturing & Industrial biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development oncology pharma
Locations	Locations Mont-Saint-Guibert, BE HQ Charleroi, BE Ganshoren, BE Chuo City, JP Chuo City, JP Basel, CH Durham, US see more	Locations Lyon, FR HQ Chiyoda City, JP Cambridge, US	Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more
Employees	Employees 185% decrease	Employees 6	Employees 18,0006% increase	Employees 75,883
Valuation ($)	Valuation ($) N/A	Valuation ($) 18.3 m	Valuation ($) 110.5 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €6.6m (FY, 2024)	Revenue (est.) $29.4b (FY, 2025)	Revenue (est.) $56.7b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods €2.8m (FY, 2024)	Cost of goods $6.2b (FY, 2025)	Cost of goods $8.4b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit €3.8m (FY, 2024)	Gross profit $23.2b (FY, 2025)	Gross profit $49.8b (FY, 2025)
Net income	Net income N/A	Net income (€18.3m) (FY, 2024)	Net income $8.5b (FY, 2025)	Net income $14b (FY, 2025)
Operating ⚠
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 9 (FY, 2021)	Phase III Trials Products 44 (FY, 2022)
Phase III Trials Products (Oncology)	Phase III Trials Products (Oncology) N/A	Phase III Trials Products (Oncology) N/A	Phase III Trials Products (Oncology) 4 (FY, 2021)	Phase III Trials Products (Oncology) 27 (FY, 2021)
Funding
Total funding raised	Total funding raised $ 146m	Total funding raised $ 33.8m	Total funding raised N/A	Total funding raised $ 6.5m